Trial reportMolecular imaging and biology2025
Detection of Prostate Cancer Metastases During Pelvic Lymph Node Dissection with the PSMA-Targeted Fluorescent Agent OTL78: A Phase II Study.
Trial report in Molecular imaging and biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to assess the feasibility of intraoperative fluorescence imaging using the PSMA-targeted fluorescent tracer OTL78 for detecting lymph node metastases during pelvic lymph node dissection (PLND) in patients undergoing staging or salvage surgery for prostate cancer. PROCEDURES: In a prospective pilot study, six patients scheduled for robot-assisted PLND received a single intravenous infusion of OTL78 at a dose of either 0.06 mg/kg or 0.03 mg/kg, administered 1-2 h prior to surgery. Intraoperatively, lymph node clusters were evaluated using fluorescence imaging. Post-surgical histopathological analysis and immunohistochemistry were performed to confirm tumor presence and PSMA overexpression in fluorescent nodes. The primary outcome was the feasibility of fluorescence imaging in detecting metastatic lymph nodes during PLND.
resultsFluorescence imaging demonstrated a sensitivity of 66.7% and specificity of 91.7% for identifying metastatic lymph nodes. The positive predictive value was 66.7%, and the negative predictive value was 91.7%. Metastasized lymph nodes (MLN) exhibited significantly higher median fluorescence intensity (MFI) than benign lymph nodes (BLN): 0.51 [IQR 0.11-0.74] vs. 0.06 [IQR 0.03-0.12], p = 0.024. Immunohistochemistry confirmed PSMA overexpression in fluorescent malignant regions. No adverse reactions to the tracer were reported.
conclusionsIntraoperative fluorescence imaging with the tracer OTL78 is a feasible technique for identifying metastatic lymph nodes during PLND. Fluorescence guidance may assist in detecting small metastatic deposits within nodal clusters that are otherwise difficult to localize. Larger studies are needed to validate these findings and optimize the imaging protocol for broader clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.